Last reviewed · How we verify
All registered antiepileptic drugs
All registered antiepileptic drugs is a Antiepileptic drugs (heterogeneous class) Small molecule drug developed by UMC Utrecht. It is currently FDA-approved for Epilepsy (generalized and focal seizures), Status epilepticus, Seizure prophylaxis.
Antiepileptic drugs work through multiple mechanisms including sodium channel blockade, GABA enhancement, calcium channel modulation, and other pathways to reduce neuronal excitability and prevent seizures.
Antiepileptic drugs work through multiple mechanisms including sodium channel blockade, GABA enhancement, calcium channel modulation, and other pathways to reduce neuronal excitability and prevent seizures. Used for Epilepsy (generalized and focal seizures), Status epilepticus, Seizure prophylaxis.
At a glance
| Generic name | All registered antiepileptic drugs |
|---|---|
| Sponsor | UMC Utrecht |
| Drug class | Antiepileptic drugs (heterogeneous class) |
| Target | Multiple targets including voltage-gated sodium channels, GABA receptors, calcium channels, SV2A, and others depending on specific agent |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Antiepileptic drugs (AEDs) comprise a diverse class with heterogeneous mechanisms of action. Common mechanisms include inhibition of voltage-gated sodium channels (phenytoin, carbamazepine, lamotrigine), enhancement of GABAergic inhibition (benzodiazepines, barbiturates, valproate), modulation of T-type and L-type calcium channels (ethosuximide, gabapentin), and other mechanisms such as SV2A binding (levetiracetam) or carbonic anhydrase inhibition (topiramate). These mechanisms collectively reduce seizure threshold and neuronal firing.
Approved indications
- Epilepsy (generalized and focal seizures)
- Status epilepticus
- Seizure prophylaxis
- Neuropathic pain (off-label for some agents)
- Bipolar disorder (off-label for some agents)
Common side effects
- Dizziness
- Ataxia
- Somnolence
- Headache
- Nausea
- Diplopia
- Rash (including Stevens-Johnson syndrome)
- Hepatotoxicity
- Hyponatremia
Key clinical trials
- Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme (PHASE1, PHASE2)
- Study to Improve the Treatment of Epilepsy (SITE) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- All registered antiepileptic drugs CI brief — competitive landscape report
- All registered antiepileptic drugs updates RSS · CI watch RSS
- UMC Utrecht portfolio CI
Frequently asked questions about All registered antiepileptic drugs
What is All registered antiepileptic drugs?
How does All registered antiepileptic drugs work?
What is All registered antiepileptic drugs used for?
Who makes All registered antiepileptic drugs?
What drug class is All registered antiepileptic drugs in?
What development phase is All registered antiepileptic drugs in?
What are the side effects of All registered antiepileptic drugs?
What does All registered antiepileptic drugs target?
Related
- Drug class: All Antiepileptic drugs (heterogeneous class) drugs
- Target: All drugs targeting Multiple targets including voltage-gated sodium channels, GABA receptors, calcium channels, SV2A, and others depending on specific agent
- Manufacturer: UMC Utrecht — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Epilepsy (generalized and focal seizures)
- Indication: Drugs for Status epilepticus
- Indication: Drugs for Seizure prophylaxis
- Compare: All registered antiepileptic drugs vs similar drugs
- Pricing: All registered antiepileptic drugs cost, discount & access